Will GoodRX Stock Bounce Back?
GoodRX (NASDAQ:GDRX) tracks prescription drug prices and its model was…
Sell
9
GPCR Quote, Financials, Valuation and Earnings
Last price:
$19.55
Seasonality move
:
32.88%
Day range:
$18.94 - $19.74
52-week range:
$13.22 - $45.37
Dividend yield:
0%
P/E ratio:
--
P/S ratio:
--
P/B ratio:
1.37x
Volume:
544.9K
Avg. volume:
766K
1-year change:
-56.11%
Market cap:
$1.1B
Revenue:
--
EPS (TTM):
-$2.59
Analysts' Opinion
-
Consensus RatingStructure Therapeutics has received a consensus rating of Buy. The company's average rating is a Buy based on 7 Buy ratings, 0 Hold ratings, and 0 Sell ratings.
-
Price Target UpsideAccording to analysts' consensus price target of $75.81, Structure Therapeutics has an estimated upside of 286.77% from its current price of $19.60.
-
Price Target DownsideAccording to analysts, the lowest downside price target is $37.50 representing -91.33% downside risk from its current price of $19.60.
Fair Value
-
According to the consensus of 7 analysts, Structure Therapeutics has 286.77% upside to fair value with a price target of $75.81 per share.
GPCR vs. S&P 500
-
Over the past 5 trading days, Structure Therapeutics has overperformed the S&P 500 by 2.55% suggesting its relative strength compared to the major market average is strong at this time.
Share Buyback
-
Structure Therapeutics does have a share repurchase program in place at this time. The scale of a buyback program can materially affect share price and usually results in a higher earnings per share, all else being equal, when the share count drops.
Revenue Growth
-
Structure Therapeutics has grown year-over-year revenues for 0 quarters straight. In the most recent quarter Structure Therapeutics reported revenues of --.
Earnings Growth
-
Structure Therapeutics has grown year-over-year earnings for 0 quarters straight. In the most recent quarter Structure Therapeutics reported earnings per share of -$0.81.
Enterprise value:
290.8M
EV / Invested capital:
--
Price / LTM sales:
--
EV / EBIT:
--
EV / Revenue:
--
PEG ratio (5yr expected):
--
EV / Free cash flow:
-2.14x
Price / Operating cash flow:
--
Enterprise value / EBITDA:
--
Gross Profit (TTM):
--
Return On Assets:
--
Net Income Margin (TTM):
--
Return On Equity:
--
Return On Invested Capital:
--
Operating Margin:
--
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Income Statement | ||||||
| Revenue | -- | -- | -- | -- | -- | |
| Gross Profit | -- | -- | -- | -- | -- | |
| Operating Income | -$59.3M | -$115.1M | -$182.5M | -$32M | -$56.3M | |
| EBITDA | -$59M | -$114.7M | -$181.5M | -$31.8M | -$56M | |
| Diluted EPS | -$2.15 | -$2.28 | -$2.59 | -$0.57 | -$0.81 | |
| Period Ending | 2021-03-31 | 2022-03-31 | 2023-03-31 | 2024-03-31 | 2025-03-31 | |
|---|---|---|---|---|---|---|
| Balance Sheet | ||||||
| Current Assets | -- | -- | $246.2M | $449.4M | $849.6M | |
| Total Assets | -- | -- | $247.4M | $457.2M | $866.5M | |
| Current Liabilities | -- | -- | $11M | $23.6M | $36.5M | |
| Total Liabilities | -- | -- | $11M | $27.4M | $41.9M | |
| Total Equity | -- | -- | $236.4M | $429.8M | $824.6M | |
| Total Debt | -- | -- | -- | -- | -- | |
| Trailing 12 Months | Fiscal Quarters | |||||
|---|---|---|---|---|---|---|
| Period Ending | 2023-03-31 | 2024-03-31 | 2025-03-31 | 2024-03-31 | 2025-03-31 | |
| Cash Flow Statement | ||||||
| Cash Flow Operations | -$52.9M | -$93.3M | -$134.8M | -$34.1M | -$52.2M | |
| Cash From Investing | -$71.4M | -$217.9M | -$326.3M | $1.4M | $34M | |
| Cash From Financing | $200.2M | $282.5M | $515.4M | $702K | $809K | |
| Free Cash Flow | -$53M | -$95.6M | -$136.2M | -$34.2M | -$52.5M | |
GPCR
Sector
Market Cap
$1.1B
$34.4M
Price % of 52-Week High
43.2%
48.88%
Dividend Yield
0%
0%
Shareholder Yield
--
-1.01%
1-Year Price Total Return
-56.11%
-37.36%
Beta (5-Year)
--
0.614
Dividend yield:
0%
Annualized payout:
$0.00
Payout ratio:
--
Growth streak:
0 years
Technicals
8-day SMA
Buy
Level
$19.11
200-day SMA
Sell
Level
$27.23
Bollinger Bands (100)
Sell
Level
18.66 - 24.42
Chaikin Money Flow
Sell
Level
-780.7K
20-day SMA
Sell
Level
$20.38
Relative Strength Index (RSI14)
Sell
Level
41.51
ADX Line
Buy
Level
19.74
Williams %R
Neutral
Level
-69.4868
50-day SMA
Sell
Level
$22.25
MACD (12, 26)
Buy
Level
5.27
25-day Aroon Oscillator
Sell
Level
-76
On Balance Volume
Neutral
Level
2.2M
Financial Scores
--
Altman Z-Score
(Annual)
Level (--)
--
CA Score
(Annual)
Level (--)
--
Beneish M-Score
(Annual)
Level (--)
Buy
Momentum Score
Level (3)
--
Ohlson Score
Level (--)
--
Piotroski F Score
(Annual)
Level (--)
--
Quality Ratio Score
Level (--)
--
Fundamental Score
Level (--)
Revenue Forecast
Earnings per Share Forecast
Company Profile
Structure Therapeutics Inc is a clinical-stage biopharmaceutical company developing novel oral small-molecule therapeutics to treat a wide range of chronic diseases with unmet medical needs. Its differentiated technology platform leverages both structure-based drug discovery and expertise in computational chemistry to discover and develop small molecule therapeutics against G-protein coupled receptors (GPCRs). The group operates and manages its business as one reportable and operating segment, which is the business of research and development of medicines that target chronic diseases with unmet medical needs.
Stock Forecast FAQ
In the current month, GPCR has received 7 Buy ratings 0 Hold ratings, and 0 Sell ratings. The GPCR average analyst price target in the past 3 months is $75.81.
-
Where Will Structure Therapeutics Stock Be In 1 Year?
According to analysts, the consensus estimate is that Structure Therapeutics share price will rise to $75.81 per share over the next 12 months.
-
What Do Analysts Say About Structure Therapeutics?
Analysts are divided on their view about Structure Therapeutics share price and where it will be in the next 12 months. The majority of analysts rate the stock a Buy. However, a smaller subset of analysts suggest that Structure Therapeutics is a Sell and believe this share price will drop from its current level to $37.50.
-
What Is Structure Therapeutics's Price Target?
The price target for Structure Therapeutics over the next 1-year time period is forecast to be $75.81 according to 7 Wall Street analysts, 7 of them rate the stock a Buy, 0 rate the stock a Sell, and 0 analysts rate the stock a Hold.
-
Is GPCR A Buy, Sell Or Hold?
According to Wall Street analysts, the consensus rating for Structure Therapeutics is a Buy. 7 of 7 analysts rate the stock a Buy at this time.
-
How Can I Buy Shares Of GPCR?
You can purchase shares of Structure Therapeutics via an online brokerage firm such as TD Ameritrade.com, thinkorswim.com, e-trade.com, tastytrade.com, or Schwab.com. Many other digital online brokerages exist such as RobinHood and Webull where you can purchase Structure Therapeutics shares.
-
What Is The Structure Therapeutics Share Price Today?
Structure Therapeutics was last trading at $19.55 per share. This represents the most recent stock quote for Structure Therapeutics. Yesterday, Structure Therapeutics closed at $19.60 per share.
-
How To Buy Structure Therapeutics Stock Online?
In order to purchase Structure Therapeutics stock online, open a brokerage account, deposit funds into the account, and select an order type to purchase shares whether it be market or limit.
SEE THE 1% OF STOCKS YOU NEED TO OWN FOR MASSIVE RETURNS
GET BETTER TRADE IDEAS
Popular
Will FCX Benefit From Tariffs?
Freeport-McMoRan (NYSE:FCX) is among the world’s largest producers of copper…
Can Levi Stock Double?
Levi Strauss (NYSE:LEVI) is among the oldest clothing brands in…
Stock Ideas
Buy
70
Is NVDA Stock a Buy?
Market Cap: $4.2T
P/E Ratio: 58x
Buy
62
Is MSFT Stock a Buy?
Market Cap: $3.8T
P/E Ratio: 43x
Sell
40
Is AAPL Stock a Buy?
Market Cap: $3.1T
P/E Ratio: 35x
Alerts
Buy
82
SBET alert for Jul 17
SharpLink Gaming [SBET] is down 2.6% over the past day.
Buy
89
EXOD alert for Jul 17
Exodus Movement [EXOD] is down 4.14% over the past day.
Buy
60
U alert for Jul 17
Unity Software [U] is up 7.51% over the past day.
